1017 related articles for article (PubMed ID: 25961827)
21. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1.
Yellen P; Saqcena M; Salloum D; Feng J; Preda A; Xu L; Rodrik-Outmezguine V; Foster DA
Cell Cycle; 2011 Nov; 10(22):3948-56. PubMed ID: 22071574
[TBL] [Abstract][Full Text] [Related]
22. 4E-BP1, a multifactor regulated multifunctional protein.
Qin X; Jiang B; Zhang Y
Cell Cycle; 2016; 15(6):781-6. PubMed ID: 26901143
[TBL] [Abstract][Full Text] [Related]
23. Snail determines the therapeutic response to mTOR kinase inhibitors by transcriptional repression of 4E-BP1.
Wang J; Ye Q; Cao Y; Guo Y; Huang X; Mi W; Liu S; Wang C; Yang HS; Zhou BP; Evers BM; She QB
Nat Commun; 2017 Dec; 8(1):2207. PubMed ID: 29263324
[TBL] [Abstract][Full Text] [Related]
24. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
[TBL] [Abstract][Full Text] [Related]
25. p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.
Cam M; Bid HK; Xiao L; Zambetti GP; Houghton PJ; Cam H
J Biol Chem; 2014 Feb; 289(7):4083-94. PubMed ID: 24366874
[TBL] [Abstract][Full Text] [Related]
26. Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1.
Völkers M; Toko H; Doroudgar S; Din S; Quijada P; Joyo AY; Ornelas L; Joyo E; Thuerauf DJ; Konstandin MH; Gude N; Glembotski CC; Sussman MA
Proc Natl Acad Sci U S A; 2013 Jul; 110(31):12661-6. PubMed ID: 23842089
[TBL] [Abstract][Full Text] [Related]
27. Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis.
Gardner TW; Abcouwer SF; Losiewicz MK; Fort PE
Am J Physiol Endocrinol Metab; 2015 Sep; 309(6):E546-56. PubMed ID: 26199279
[TBL] [Abstract][Full Text] [Related]
28. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
29. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
He K; Zheng X; Li M; Zhang L; Yu J
Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
[TBL] [Abstract][Full Text] [Related]
30. Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.
Sathe A; Chalaud G; Oppolzer I; Wong KY; von Busch M; Schmid SC; Tong Z; Retz M; Gschwend JE; Schulz WA; Nawroth R
PLoS One; 2018; 13(1):e0190854. PubMed ID: 29357370
[TBL] [Abstract][Full Text] [Related]
31. Reappraisal to the study of 4E-BP1 as an mTOR substrate - A normative critique.
Batool A; Aashaq S; Andrabi KI
Eur J Cell Biol; 2017 Jun; 96(4):325-336. PubMed ID: 28427795
[TBL] [Abstract][Full Text] [Related]
32. mTORC1 signalling and eIF4E/4E-BP1 translation initiation factor stoichiometry influence recombinant protein productivity from GS-CHOK1 cells.
Jossé L; Xie J; Proud CG; Smales CM
Biochem J; 2016 Dec; 473(24):4651-4664. PubMed ID: 27760840
[TBL] [Abstract][Full Text] [Related]
33. Translation control during prolonged mTORC1 inhibition mediated by 4E-BP3.
Tsukumo Y; Alain T; Fonseca BD; Nadon R; Sonenberg N
Nat Commun; 2016 Jun; 7():11776. PubMed ID: 27319316
[TBL] [Abstract][Full Text] [Related]
34. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.
Wang L; Harris TE; Lawrence JC
J Biol Chem; 2008 Jun; 283(23):15619-27. PubMed ID: 18372248
[TBL] [Abstract][Full Text] [Related]
35. Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.
Bhagwat SV; Gokhale PC; Crew AP; Cooke A; Yao Y; Mantis C; Kahler J; Workman J; Bittner M; Dudkin L; Epstein DM; Gibson NW; Wild R; Arnold LD; Houghton PJ; Pachter JA
Mol Cancer Ther; 2011 Aug; 10(8):1394-406. PubMed ID: 21673091
[TBL] [Abstract][Full Text] [Related]
36. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
37. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
[TBL] [Abstract][Full Text] [Related]
38. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
[TBL] [Abstract][Full Text] [Related]
39. Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Korets SB; Musa F; Curtin J; Blank SV; Schneider RJ
Gynecol Oncol; 2014 Feb; 132(2):468-73. PubMed ID: 24316308
[TBL] [Abstract][Full Text] [Related]
40. A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.
Liu P; Ge M; Hu J; Li X; Che L; Sun K; Cheng L; Huang Y; Pilo MG; Cigliano A; Pes GM; Pascale RM; Brozzetti S; Vidili G; Porcu A; Cossu A; Palmieri G; Sini MC; Ribback S; Dombrowski F; Tao J; Calvisi DF; Chen L; Chen X
Hepatology; 2017 Jul; 66(1):167-181. PubMed ID: 28370287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
